LONDON, Dec 10 () - Roche said on Wednesday its experimental oral drug giredestrant reduced the risk of breast cancer recurrence by ​30% compared with standard endocrine therapy, in what it said marked ‌the first big advance in hormonal treatment for the disease in over 20 years. The Swiss ‌drugmaker said detailed results from the phase III lidERA trial showed at three years, 92.

In southern Nepal, tigers, leopards, and rhinos are more dangerous than avalanches and altitude sickness are in the high Himalaya.

Design bloggers have become persuasive figures in the realm of style, offering an abundance of motivation, pattern bits of knowledge, and imaginative